Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tasosartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16626845 | 0.84 | AGTR1 (0.73) | AGTR1TBXA2RAGTR2PDE3A | |
| Tasosartan SCHEMBL49626 | 0.83 | AGTR1 (0.71) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL13714544 | 0.81 | AGTR1 (0.68) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL7095882 | 0.81 | AGTR1 (0.68) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL683804 | 0.79 | AGTR1 (0.66) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL7020979 | 0.79 | AGTR1 (0.65) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL683885 | 0.79 | AGTR1 (0.65) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL6664086 | 0.77 | AGTR1 (0.63) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL6664081 | 0.77 | AGTR1 (0.63) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL7430153 | 0.76 | AGTR1 (0.62) | AGTR1TBXA2RAGTR2PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8047 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20250195525-A1 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-06-19 | — | — | US | claimed |
| WO-2025125409-A1 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| CN-113056465-B | Tetrahydropyrane (THP) -substituted bicyclic pyrimidinedione compounds | 迈奥卡迪亚公司 | 2025-01-28 | — | — | CN | claimed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | claimed |
| CN-1192697-A | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure | SEARLE & CO (US) | 1998-09-09 | — | — | CN | claimed |
| WO-1998030216-A1 | USE OF ANGIOTENSIN II ANTAGONISTS TO TREAT SYMPTOMATIC HEART FAILURE | MERCK & CO., INC. (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0835106-A1 | METHOD OF TREATING RENAL DISEASE USING AN ACE INHIBITOR AND AN AII ANTAGONIST | MERCK & CO. INC. (US) | 1998-04-15 | — | — | EP | claimed |
| EP-0831910-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0831911-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997002032-A1 | METHOD OF TREATING RENAL DISEASE USING AN ACE INHIBITOR AND AN AII ANTAGONIST | MERCK & CO., INC. (US) | 1997-01-23 | — | — | WO | claimed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |